Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$4.79M
EBITDA Margin
-1670.57%
TTM Avg
-1446.66%
3Y Avg
-2067.25%
5Y Avg
-1679.39%
Market Cap
$4.80M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$4.96M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$4.11M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | $4.55M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.80M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.96M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| GRI Bio, Inc. (GRI)vs › | $4.11M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.02M | -890.82% | -527.81% | -554.45% | -445.87% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
